Home > > > > > Report Detail

Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

Publisher Name :
Date: 30-Mar-2018
No. of pages: 82

This report provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3).

It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for RSV and HPIV-3 infections, and features dormant and discontinued products.

RSV infects the lungs and breathing passages. Symptoms include cough, stuffy or runny nose, mild sore throat, earache and fever. HPIV-3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough runny nose, croup, bronchiolitis, wheezing and sore throat.

Scope


  • Which companies are the most active within the pipeline for RSV and HPIV-3 infections?

  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

  • What are the most important R&D milestones and data publications to have happened within this field?


Reasons to buy


  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6

2 Introduction 8
2.1 GBI Research Report Coverage 8
2.2 Respiratory Syncytial Virus (RSV) Infections – Overview 8
2.3 Human Parainfluenza Virus 3 Infections – Overview 8

3 Therapeutics Development 9
3.1 Respiratory Syncytial Virus (RSV) Infections 9
3.2 Human Parainfluenza Virus 3 Infections 22

4 Therapeutics Assessment 25
4.1 Respiratory Syncytial Virus (RSV) Infections 25
4.2 Human Parainfluenza Virus 3 Infections 31

5 Companies Involved in Therapeutics Development 38
5.1 Respiratory Syncytial Virus (RSV) Infections 38
5.2 Human Parainfluenza Virus 3 Infections 61

6 Dormant Projects 63
6.1 Respiratory Syncytial Virus (RSV) Infections 63
6.2 Human Parainfluenza Virus 3 Infections 67

7 Discontinued Products 68
7.1 Respiratory Syncytial Virus (RSV) Infections 68
7.2 Human Parainfluenza Virus 3 Infections 68

8 Product Development Milestones 69
8.1 Respiratory Syncytial Virus (RSV) Infections 69

9 Appendix 81
9.1 Methodology 81
9.2 Coverage 81
9.3 Secondary Research 81
9.4 Primary Research 81
9.5 Expert Panel Validation 81
9.6 Contact Us 82
9.7 Disclaimer 82

List of Tables

Table 1:  Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections 9
Table 2:  Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 11
Table 3:  Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 14
Table 4:  Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 15
Table 5:  Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 20
Table 6:  Number of Products under Development for Human Parainfluenza Virus 3 Infections 22
Table 7:  Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections 23
Table 8:  Number of Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections 24
Table 9:  Products under Development by Companies, Human Parainfluenza Virus 3 Infections 24
Table 10:  Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections 24
Table 11:  Number of Products by Stage and Target, Respiratory Syncytial Virus (RSV) Infections 26
Table 12:  Number of Products by Stage and Mechanism of Action, Respiratory Syncytial Virus (RSV) Infections 27
Table 13:  Number of Products by Stage and Route of Administration, Respiratory Syncytial Virus (RSV) Infections 29
Table 14:  Number of Products by Stage and Molecule Type, Respiratory Syncytial Virus (RSV) Infections 31
Table 15:  Number of Products by Stage and Target, Human Parainfluenza Virus 3 Infections 32
Table 16:  Number of Products by Stage and Mechanism of Action, Human Parainfluenza Virus 3 Infections 34
Table 17:  Number of Products by Stage and Route of Administration, Human Parainfluenza Virus 3 Infections 36
Table 18:  Number of Products by Stage and Molecule Type, Human Parainfluenza Virus 3 Infections 37
Table 19:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by 3-V Biosciences Inc, 38
Table 20:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abivax SA 38
Table 21:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Ablynx NV 39
Table 22:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by ADMA Biologics Inc 39
Table 23:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Agilvax Inc 40
Table 24:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Amarillo Biosciences Inc 40
Table 25:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Anima Biotech Ltd 41
Table 26:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aridis Pharmaceuticals LLC 41
Table 27:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Artificial Cell Technologies Inc 41
Table 28:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by AstraZeneca Plc 42
Table 29:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Bavarian Nordic A/S 43
Table 30:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Celltrion Inc 43
Table 31:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Curevac AG 44
Table 32:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by DBV Technologies SA 44
Table 33:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Enanta Pharmaceuticals Inc 45
Table 34:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Evec Inc 45
Table 35:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by F. Hoffmann-La Roche Ltd 46
Table 36:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gene Techno Science Co Ltd 46
Table 37:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by GenVec Inc 47
Table 38:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gilead Sciences Inc 47
Table 39:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by GlaxoSmithKline Plc 48
Table 40:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by iBio Inc 48
Table 41:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunovaccine Inc 49
Table 42:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunwork Inc 49
Table 43:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Inovio Pharmaceuticals Inc 50
Table 44:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Johnson & Johnson 51
Table 45:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Karyopharm Therapeutics Inc 51
Table 46:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Kineta Inc 52
Table 47:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by mAbxience SA 52
Table 48:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by MedImmune LLC 52
Table 49:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Medivir AB 53
Table 50:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Mymetics Corp 54
Table 51:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by NanoBio Corp 54
Table 52:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Navigen Inc 54
Table 53:    Respiratory Syncytial Virus (RSV) Infections – Pipeline by Novavax Inc 55
Table 54:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Phoenix Biotechnology Inc 55
Table 55:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Profectus BioSciences Inc 56
Table 56:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Pulmocide Ltd 56
Table 57:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by ReViral Ltd 57
Table 58:   Respiratory Syncytial Virus (RSV) Infections – Pipeline by Romark Laboratories LC 57
Table 59:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Takeda Pharmaceutical Co Ltd 58
Table 60:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by TechnoVax Inc 58
Table 61:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Themis Bioscience GmbH 58
Table 62:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vault Pharma Inc 59
Table 63:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vaxart Inc 59
Table 64:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Virometix AG 60
Table 65:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by Visterra Inc 60
Table 66:  Respiratory Syncytial Virus (RSV) Infections – Pipeline by VLP Biotech Inc 60
Table 67:  Human Parainfluenza Virus 3 Infections – Pipeline by 3-V Biosciences Inc 61
Table 68:  Human Parainfluenza Virus 3 Infections – Pipeline by Amarillo Biosciences Inc 61
Table 69:  Human Parainfluenza Virus 3 Infections – Pipeline by Ansun Biopharma Inc 62
Table 70:  Human Parainfluenza Virus 3 Infections – Pipeline by Moderna Therapeutics Inc 62
Table 71:  Respiratory Syncytial Virus (RSV) Infections – Dormant Projects 63
Table 72:  Human Parainfluenza Virus 3 Infections – Dormant Projects 67
Table 73:  Respiratory Syncytial Virus (RSV) Infections – Discontinued Products 68
Table 74:  Human Parainfluenza Virus 3 Infections – Discontinued Products 68

List of Figures

Figure 1:  Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections 9
Figure 2:  Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 10
Figure 3:  Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 13
Figure 4:  Number of Products under Development for Human Parainfluenza Virus 3 Infections 22
Figure 5:  Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections 23
Figure 6:  Number of Products by Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections 25
Figure 7:  Number of Products by Stage and Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections 25
Figure 8:  Number of Products by Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections 26
Figure 9:  Number of Products by Stage and Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections 27
Figure 10:  Number of Products by Routes of Administration, Respiratory Syncytial Virus (RSV) Infections 28
Figure 11:  Number of Products by Stage and Routes of Administration, Respiratory Syncytial Virus (RSV) Infections 28
Figure 12:  Number of Products by Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections 29
Figure 13:  Number of Products by Stage and Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections 30
Figure 14:  Number of Products by Targets, Human Parainfluenza Virus 3 Infections 31
Figure 15:  Number of Products by Stage and Targets, Human Parainfluenza Virus 3 Infections 32
Figure 16:  Number of Products by Mechanism of Actions, Human Parainfluenza Virus 3 Infections 33
Figure 17:  Number of Products by Stage and Mechanism of Actions, Human Parainfluenza Virus 3 Infections 33
Figure 18:  Number of Products by Top 10 Routes of Administration, Human Parainfluenza Virus 3 Infections 35
Figure 19:  Number of Products by Stage and Routes of Administration, Human Parainfluenza Virus 3 Infections 35
Figure 20:  Number of Products by Molecule Types, Human Parainfluenza Virus 3 Infections 36
Figure 21:  Number of Products by Stage and Molecule Types, Human Parainfluenza Virus 3 Infections 37

  • Global Carbocisteine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 102
    According to our LPI (LP Information) latest study, the global Carbocisteine market size was valued at US$ 55 million in 2023. With growing demand in downstream market, the Carbocisteine is forecast to a readjusted size of US$ 76 million by 2030 with a CAGR of 4.9% during review period. The research report highlights the growth potential of the global Carbocisteine market. Carbocisteine are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Bovine Respiratory Disease Treatment Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 120
    Report Overview: Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired host immunity, inadequate housing conditions, and environmental factors. The major factor leading to bovine respiratory diseases are host factors, environmental factors, and direct influence of infectious agents such as virus, bacteria, and parasites. However, due to increasing consumption of milk and beef products, the need for......
  • Global Ambroxol Market Research Report 2023
    Published: 01-Dec-2023        Price: US 2900 Onwards        Pages: 91
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Ambroxol market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Teva - Bayer - Novartis - Mylan - Bidachem - Hanmi - Hexal Pharma - Sris Pharmaceuticals - Hubei Ocean Biotechnology - DM Pharma......
  • Global Carbocisteine Professional Survey Report 2023, Forecast to 2028
    Published: 23-Nov-2023        Price: US 3280 Onwards        Pages: 101
    Carbocisteine is a type of medicine called a mucolytic. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to de......
  • Global Carbocisteine Market Research Report 2023, Forecast to 2028
    Published: 23-Nov-2023        Price: US 2680 Onwards        Pages: 136
    Carbocisteine is a type of medicine called a mucolytic. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to de......
  • Global Bovine Respiratory Disease Treatment Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 09-Nov-2023        Price: US 3380 Onwards        Pages: 99
    Market Overview of Global Bovine Respiratory Disease Treatment market: According to our latest research, the global Bovine Respiratory Disease Treatment market looks promising in the next 5 years. As of 2022, the global Bovine Respiratory Disease Treatment market was estimated at USD 1748.69 million, and it's anticipated to reach USD 2423.79 million in 2028, with a CAGR of 5.59% during the forecast years. Bovine respiratory disease (BRD) is a multifactorial and complex diseas......
  • Respiratory Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 200
    Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of respiratory deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding......
  • Global Drugs For Respiratory Syncytial Virus (Rsv) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Sep-2023        Price: US 3380 Onwards        Pages: 106
    Market Overview of Global Drugs For Respiratory Syncytial Virus (Rsv) market: According to our latest research, the global Drugs For Respiratory Syncytial Virus (Rsv) market looks promising in the next 5 years. As of 2022, the global Drugs For Respiratory Syncytial Virus (Rsv) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and......
  • Global Ambroxol Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Sep-2023        Price: US 3380 Onwards        Pages: 127
    Market Overview of Global Ambroxol market: According to our latest research, the global Ambroxol market looks promising in the next 5 years. As of 2022, the global Ambroxol market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Ambroxol market, with a systematical descriptio......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs